Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of Maintenance Abemaciclib/Letrozole After Systemic Therapy in Patients With Advanced or Recurrent Estrogen Receptor Positive, Mismatch Repair Proficient, TP53 Wildtype Endometrial Cancer

NCT06366347 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT06366347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06366347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of Maintenance Abemaciclib/Letrozole After Systemic Therapy in Patients With Advanced or Recurrent Estrogen Receptor Positive, Mismatch Repair Proficient, TP53 Wildtype Endometrial Cancer
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 2
Overall status
Recruiting
Start date
September 25, 2024
Completion date
March 1, 2029
Enrollment
32 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, recurrent endometrial cancer, tp53